DSM-Firmenich

Q3 FY26: The upgrade was already in the price

04/11/26 -"DSM-Firmenich delivered another solid quarter, although the headline beat masks mixed divisional performance. Fragrances remain the main growth engine, while softer TTH growth raised concerns despite ..."

PDF page sample
Pages
64
Language
English
Published on
04/11/26
Download
You may also be interested by these reports :
04/11/26
Middle East disruption weighed on the quarter. Earnings fell as Jubail stayed idle and soda ash demand softened; pass-through pricing lagged cost ...
04/11/26
DSM-Firmenich delivered another solid quarter, although the headline beat masks mixed divisional performance. Fragrances remain the main growth ...
04/11/26
Solvay’s Q3 results had disclosed the negative surprises in its 19 October pre-release. Sales fell on lower volumes, chiefly the idled Jubail ...
03/11/26
Clariant’s Q3 2026 growth was price-led, though underlying volumes improved in Care Chemicals and A&A. Middle East conflict weighed on Catalysts. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO